Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.
A recent study presented at ASCO 2026 indicates that administering hormone therapy before surgery in prostate cancer patients can significantly reduce relapse rates, suggesting a potential shift in treatment protocols.
A recent study presented at ASCO 2026 indicates that administering hormone therapy before surgery in prostate cancer patients can significantly reduce relapse rates, suggesting a potential shift in treatment protocols.
READ MORE
Pfizer expands its oncology portfolio through a substantial partnership agreement with Innovent Biologics, aiming to develop and commercialize a dozen novel antibody-based cancer therapies.
Kailera Therapeutics is advancing a portfolio of weight loss treatments closely aligned with Eli Lilly’s established GLP-1 and GIP dual agonist medicines, signaling competitive strides in obesity therapeutics.
In today's employer-driven market, biopharma professionals face unique challenges when negotiating job offers. Experts weigh in on whether negotiation is advisable, common pitfalls, and strategic tips.
In 2025, the highest paid pharma CEOs earned a combined total of $157.8 million, reflecting the substantial financial rewards at the leadership level within the pharmaceutical sector.
Niowave, after securing key partnerships with pharmaceutical giants like Novartis and AstraZeneca, has initiated the construction of a $75 million radioisotope production facility aimed at increasing supply of actinium-225 for next-generation radiopharmaceuticals.
Eli Lilly has expanded its vaccine portfolio and infectious disease capabilities by acquiring three biotech companies for a total valuation of up to $3.8 billion, reinforcing its position at the forefront of vaccine development and innovation.
In an unprecedented achievement, Eli Lilly has secured the top spot in both innovation and invention categories in IDEA Pharma’s annual analysis, underscoring its significant market success and multiple FDA approvals.
Datroway, developed through a collaboration between AstraZeneca and Daiichi Sankyo, has received FDA approval as a first-line treatment for triple negative breast cancer, marking a significant milestone in addressing this challenging cancer subtype.
Gilead Sciences has signed a $140 million agreement with Korea’s Yuhan to supply active pharmaceutical ingredients (APIs), enhancing their strategic manufacturing partnerships.
Leaders from health care and science convened at STAT's Breakthrough Summit West to tackle key issues including biotech security and advancements in longevity research.
